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Angiogenesis (neoangiogenesis), a process of neovascularization, is an essential step for local tumor growth and distant metastasis  
formation. We have analysed angiogenesis status: vascular architecture, microvessel density, and vascular endothelial growth factors 
expression in 62 adrenal pheochromocytomas: 57 benign and 5 malignant. Immunohistochemical evaluation revealed that vascular 
architecture and vessel density are different in the central and subcapsular areas of the tumor. Furthermore, we have observed a 
strong correlation between number of macrophages and microvessel density in the central and subcapsular areas of the tumor 
and between the expression of VEGF-A in tumor cells and microvessel density in central and subcapsular areas of the tumor. 
Secondary changes in these tumors influence the results and both vascular architecture and microvessel density are markedly 
disturbed by hemorrhagic and cystic changes in pheochromocytomas. These changes are partially caused by laparoscopic operation 
technique. However, no differences in vascular parameters were found between pheochromocytomas with benign and malignant 
clinical behavior. Our observation showed that analysis of angiogenesis, as a single feature, does not help in differentiating malignant 
and benign pheochromocytomas and has no independent prognostic significance. On the other hand, high microvessel density in 
pheochromocytoma is a promising factor for antiangiogenic therapy in malignant cases.
1. Introduction
Adrenal pheochromocytoma (PCC) is an uncommon, neu-
roendocrine, catecholamine-secreting tumour arising from
chromaffin cells of the adrenal medulla [1, 2]. Its clinical
behavior is uncertain [3–5]. The histological separation
between benign and malignant cases is usually difficult, and
a definitive diagnosis of malignant PCC should be restricted
to lesions displaying distant metastases [1, 2]. Metastases
are defined by the finding of tumour cells in sites where
chromaffin cells are normally absent [6]. According to most
authors, recurrent disease occurring months or even years
after the initial operation allows for classification of the
tumour to a malignant group [1, 6, 7]. The most common
metastatic sites are lymph nodes, liver, lungs, and bones
[1, 2, 8]. PASS criteria (Pheochromocytoma of the Adrenal
Gland Scaled Score) were proposed in 2002 as a tool for
differentiating between benign and malignant cases [9] but
this scoring system is not perfect and has some limitations.
Using this scale, a significant proportion of PCC receives
boundary PASS values (PASS = 4 or 5) which do not allow
for an unequivocal assignment of the tumor to a benign or
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malignant group. It is necessary to find additional features
that allow better prediction of the clinical malignant behavior
of the tumor (future recurrence or metastasis). Microvessel
density (MVD) may be such parameter.
Neoangiogenesis, a process of neovascularization, is a
complex phenomenon which plays a vital role in many phys-
iological processes like organ development, wound healing,
and tissue regeneration as well as in the pathology of many
diseases, especially inflammatory and neoplastic diseases
[10]. Angiogenesis is also essential for tumor growth and
metastasis formation. Cancers, after a so-called angiogenic
switch, acquire the ability to induce new vessel formation.
The process of neovascularization depends on the ability to
release specific factors stimulating and inhibiting new blood
vessel formation. Both blood vessels formation stimulating
and inhibiting factors can be released by neoplastic cells, stro-
mal components, and immune cells like macrophages. Many
strategies are used to evaluate the role of neoangiogenesis in
tumor progression, and one of them is assessing microvessel
density (MVD) [11, 12].
The aim of the study was to compare MVD, expression
of vascular endothelial growth factors (VEGF-A, VEGF-C,
and VEGF-D), and the number of macrophages in different
areas of 57 benign and 5 malignant tumors and to determine
if angiogenesis evaluation can be useful in routine pathomor-
phological practice for predicting the clinical outcome of a
particular PCC tumor.
2. Material and Methods
The PCC samples were obtained from the Pathomorphol-
ogy Department, Medical College Jagiellonian University
(MCJU) in Krakow, Poland. The study was approved by the
Jagiellonian University Bioethical Committee (KBET/82/B/
2010).
Thematerial under study consisted of 62 PCCs diagnosed
in 58 patients (30males and 28 females) in the Pathomorphol-
ogy Department of MCJU during a period of 15 years from
1996 to 2010. Four patients, three women and one man, had
bilateral tumours. Seven patients were known to have one of
the syndromes associatedwith increased incidence of adrenal
pheochromocytoma (two patients with MEN 2A syndrome,
four with NF, and one with VHL syndrome). Three of these
patients (two with MEN 2A and one with NF syndrome) had
bilateral tumours. Ten patients were 30 or younger—only one
tumor in this group presented malignant clinical behaviour.
The mean tumour diameter was 4.98 cm (median: 4.2 cm,
range: 1.5–13 cm, SD = 2.38) with no significant difference
between male and female group (5.1 and 4.9 cm, resp.)—
Table 1.
Five tumours were malignant: three PCCs gave distant
metastases (to liver, lungs, and bones) and two had locally
recurred. All PCCs with a malignant clinical course were
unilateral. Clinical data were derived from patients’ records
and were available in 49 of the 58 cases (mean time of the
follow-up: 46.3 months, median: 39 months). Nine cases
were lost to follow-up, but we know that these patients
were not treated for any recurrence and/or metastasis in our
department.
Table 1: Characteristics of patients with the diagnosis of pheochro-
mocytoma.
Male Female Total
Age (y) 48.4 46.9 47.6
Site
Left 11 17 24
Right 17 13 34
Unknown 3 1 4
Diameter (cm) 5.1 4.9 5.0
PASS 4.09 4.25 4.17
Haematoxylin and eosin-stained slides and paraffin
blocks from tumors and adjacent adrenal glands were avail-
able in all 62 cases. Each diagnosis of PCC was reevaluated
and confirmed by immunohistochemical staining with four
antibodies against chromogranin A (CrA), synaptophysin
(Syn), S-100 protein (S-100), and melan A [13]. Tumour cell
immunoreactivity for chromogranin and synaptophysin with
simultaneous lack of immunoreactivity for melan A and the
presence of S-100 positive elongated cells, at least focally,
was taken as confirmation of the diagnosis of PCC. Severity
of haemorrhagic changes in the tumor was estimated in
each case. The hemorrhagic changes within the tumor were
scored from 0 (none orminimal) to 3 (extensive hemorrhagic
changes disrupting at least half of the tumor surface visible in
the histological slides).
In each case, a single H-E section and correspond-
ing paraffin block including well-preserved tumor tissue
as well as capsule were chosen, and seven 3 𝜇m sections
were prepared from the paraffin block. MVD was evalu-
ated after immunostaining endothelial cells with antibodies
against CD31 and CD105 for blood vessels and D2-40 for
lymphatic vessels. Additionally, the expression of vascular
endothelial growth factors (VEGF-A, VEGF-C, and VEGF-
D) was evaluated. Immunohistochemistry was performed by
standard method: the slides were dewaxed, rehydrated, and
incubated in 3% peroxide solution for 10 minutes to block
the endogenous peroxidase activity. Antigen retrieval was
carried out by microwaving in citrate buffer (pH 6.0) or
EDTA for 5 minutes at 700W and then for 5 minutes at
600W. The Lab-Vision (Thermo Fisher Scientific, Waltham,
USA) detection system was used. 3-Amino-9-ethylcarbazole
served as the chromogen.The slides were counterstainedwith
Mayer’s haematoxylin (DAKO, Denmark). The primary anti-
bodies and the respective technical details are summarised in
Table 2.
Positive structures (Figures 3 and 4), morphologically
identifiable vessels and collections of immunopositive cells as
well as single endothelial cells, were counted independently
by two of the authors (MB and GD) who were blinded to
the clinical and pathological data in two different areas of
the tumor: the subcapsular and intratumoral spaces of each
tumor. The subcapsular space was defined as the area within
one high power field (0.5mm) beneath the outer border of
the tumor. The remainder of the tumor was defined as the
intratumoral (central) area.
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Table 2: Primary antibodies used in the study.
Specificity Clone Manufacturer Dilution Antigen retrieval
CD31 JC70A DAKO, Denmark 1 : 20 EDTA
CD105 4G11 Novocastra 1 : 50 Citrate buffer
D2-40 D2-40 Covance Ready to use Citrate buffer
VEGF-A Polyclonal Santa Cruz 1 : 100 EDTA
VEGF-C Polyclonal Santa Cruz 1 : 100 —
VEGF-D 78923 R&D Systems 1 : 200 EDTA
CD68 PG-M1 DAKO, Denmark 1 : 50 EDTA
Table 3: The vessel counts in the whole study group of PCCs.
Marker Location Method Mean Min. Max. SD
CD31
Subcapsular Hot spot 56.88 15.00 120.00 23.72
Intratumoral Hot spot 60.07 19.00 142.00 27.91
Subcapsular Chalkey 40.31 0.00 75.68 13.54
Intratumoral Chalkey 46.08 0.00 79.08 14.37
CD105
Subcapsular Hot spot 30.15 6.00 120.00 20.84
Intratumoral Hot spot 37.91 9.00 124.00 24.48
Subcapsular Chalkey 23.51 0.00 70.58 12.75
Intratumoral Chalkey 33.15 0.00 64.63 15.22
D2-40
Capsular Hot spot 1.92 0.00 7.00 1.34
Subcapsular Hot spot 0.12 0.00 4.00 0.56
Intratumoral Hot spot 0.00 0.00 0.00 —
Two different methods of counting were used. In the first
method the number of all vessels in 10 high power fields, HPF
(×10 ocular, ×40 objective), was added up after prescanning
on lowmagnification (×10 ocular,×10 objective) to choose the
area with the impression of the highest vessel profiles number
(“hot spot”) in the intratumoral space. In the subcapsular area
all vessels in 10 consecutive HPF were counted. The result
calculated was the mean count of vessels for one HPF. In
the secondmethod, theChalkley eyepiece graticule (Chalkley
grid area 0.196mm2) with 25 randomly positioned dots
was applied to the ocular of the Olympus microscope. On
higher magnification (×10 ocular, ×40 objective) a Chalkley
eyepiece graticule was applied to each “hot spot” area and
then orientated and rotated so that the maximum number of
points would hit on or within the vessel structure in the “hot
spot” area. In the Chalkley method dots are counted, not the
individual vessels. The Chalkley count was expressed as the
total number of dots per square millimeter.
Lymphatic vessels (after D2-40 immunostaining
(Figure 5)) were counted subcapsularly in 10 consecutive
HPF and in 10 HPF in the intratumoral space.
Macrophages were counted in 10 HPF after prescanning
on low magnification (×10 ocular, ×10 objective) to choose
the area with higher cell density.The result calculated was the
mean count of CD68 positive cells for one HPF.
The extent of immunoreactivity for VEGFs was expressed
as the sum of grade and intensity of staining. Staining was
graded according to the percentage of positive tumour cells
(0: no staining; 1: <10%; 2: 10–50%; 3: 51–100% of positive
cells). Intensity of staining was described as none (0), weak
(1), moderate (2), or strong (3) (Figures 6–9). As a result,
combined VEGF immunoreactivity could range from 0
to 6. All evaluations were done using an Olympus BX51
microscope equipped with a 40x UPlanFLN eyepiece (field
of view diameter: 0.55mm).
Statistical analysis was performed using Statistica 10
(StatSoft Inc., Tulsa, USA). Comparison between groups
was done with Student’s 𝑡-test, Mann-Whitney 𝑈 test, and
Kruskall-Wallis ANOVA test; the relationship between vari-
ables was assessed using Spearman’s correlation coefficient.
The significance level was set to 0.05.
3. Results
The material consisted of 62 cases of PCC from 58 patients:
30 males and 28 females. Three females and one man had
bilateral PCC.The average age of the patients was 47.66 years
(range: 19 to 75, SD: 15.41). The age in males and females
(48.42 versus 46.90) did not differ significantly. 29 tumors
(46.8%) were located at the right adrenal gland, 21 tumors
(33.9%) were located at the left adrenal gland, and in 4
patients tumors were bilateral. In 4 cases (6.4%) laterality was
not stated.
Angiogenesis was evaluated by MVD by two different
methods. The overall results showing the number of blood
vessels in the subcapsular and central areas of tumors are
summarized in Table 3.
In both counting methods, MVD in the central areas of
the tumors was higher than in the subcapsular areas. Strong
correlation was found between both the numbers of CD31
4 International Journal of Endocrinology
Table 4: Correlation between the number of macrophages and the number of CD31 and CD105 positive blood vessels in subcapsular and
central areas of the tumors.
CD68 CD31 CD105
Subcapsular Intratumoral Subcapsular Intratumoral
Subcapsular 𝑟 = 0.4534 𝑟 = 0.4803 𝑟 = 0.6013 𝑟 = 0.5701
Intratumoral 𝑟 = 0.4972 𝑟 = 0.5391 𝑟 = 0.5806 𝑟 = 0.6124
Mean
Mean ± SE
Mean ± 1.96 ∗ SE
46
44
42
40
38
36
34
32
30
28
26
24
Subcapsular Intratumoral
Figure 1: Number of CD105 positive blood vessels in subcapsular
and central areas of the tumors.
positive blood vessels in subcapsular and central areas of the
tumors (𝑟 = 0.8653, 𝑃 < 0.001) and between the numbers
of CD105 positive blood vessels in subcapsular and central
areas of the tumors (𝑟 = 0.8837, 𝑃 < 0.01)—Figure 1. The
difference between the variables for CD105 positive vessels
was statistically significant (30.155 versus 37.91, Student’s 𝑡-test
𝑃 < 0.001).
Lymphatic vessels were absent in central parts of all
investigated PCCs. In 4 cases (6,4%) single lymphatic D2-40
positive vessels were present in subcapsular areas. In 55 PCCs
few lymphatic vessels were present within the capsule.
Mean subcapsular CD68 positive cell count was 27.68
(range: 4 to 87, SD: 18.97); mean intratumoral CD68 positive
cell count was 36.14 (range: 11 to 97, SD: 21.24)—Figure 2.
Strong correlation was found between the numbers of
macrophages in subcapsular and central parts of the tumors
(𝑟 = 0.9166, 𝑃 < 0.01) and the difference between the values
(27,68 versus 36,14)was statistically significant (Wilcoxon and
Student’s 𝑡-test 𝑃 < 0.001).
Strong correlation was found between the number of
macrophages and the number of CD31 positive blood vessels
and between the number of macrophages and CD105 positive
blood vessels in subcapsular and central parts of the tumors—
all correlation coefficients were statistically significant (𝑃 <
0.0001)—Table 4.
The detailed individual values and statistical analysis for
VEGFs expression are presented in Table 5. VEGF-A showed
the strongest expression and was correlated with the number
Mean
Mean ± SE
Mean ± 1.96 ∗ SE
44
42
40
38
36
34
32
30
28
26
22
24
Subcapsular Intratumoral
Figure 2: Number of macrophages in subcapsular and central areas
of the tumors.
Table 5: The expression of VEGF-A, VEGF-C, and VEGF-D.
Mean Min. Max. SD
VEGF-A 4.57 2 6 1.05
VEGF-C 3.58 0 6 1.09
VEGF-D 1.93 0 4 1.42
of both intratumoral and subcapsular CD31 positive and
CD105 positive vessels in both counting methods—Table 6.
No correlation was found between the expression of VEGF-
C and MVD and between VEGF-D expression and MVD.
An inverse correlation between haemorrhagic changes
and the number of CD105 positive vessels in subcapsular
parts of the tumor was found (𝑃 = 0.018).
The differences in vascular parameters between PCCs
with benign and malignant clinical behavior were slight and
not statistically significant—Table 7.
4. Discussion
Angiogenesis (neoangiogenesis, NA) is the formation of new
capillaries from already existing vessels. NA is regulated
by a variety of proteins, inter alia, vascular growth factors
and their receptors, angiogenesis modulating proteins, inte-
grins, and angiogenesis inhibitors [14–16]. NA is a com-
plex phenomenon and many strategies are used to evaluate
its role in physiological and pathological processes. Most
commonly used methods consist of assessing microvessel
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Figure 3: Numerous blood vessels with small round lumens
(immunostaining for CD31).
Figure 4: Blood vesselswith irregular, expanded lumens (immunos-
taining for CD31).
density (MVD) and expression of angiogenic factors, among
which the most important are vascular endothelial growth
factors (VEGFs) and their receptors (VEGFRs) [11, 12, 17]. NA
is essential both in nonpathological processes like embryoge-
nesis or wound healing and in tumorigenesis [10, 18] where
it is an essential step for tumor growth, progression, and
metastasis formation [11]. Formation of new blood capillaries
is also dependent on the extracellular matrix which serves
as structural support for existing and developing vessels and
on the ability of different cells to release specific factors
stimulating new blood vessel formation and factors which
downregulate vessel formation inhibitors [19]. The sources of
those factors are both neoplastic cells and various stromal and
immune cells, inter alia, macrophages. Microvascular density
can be a prognostic factor in some human cancers [17, 20, 21],
as metastasis formation is dependent on the possibility of
tumor cells to enter the lumen of small vessels and to flow
with blood to distant places and organs. Importantly, this
means that neovascularisation is necessary not only for local
tumor growth but also for allowing distant spread of the
neoplasm.
The currently accepted standard method for quantifying
tumor angiogenesis is to assess MVD based on immunohis-
tochemistry (IHC). Groups of scientists had chosen different
Figure 5: Lymphatic blood vessels present only in the tumor capsule
(immunostaining for D2-40).
Figure 6: Positive, strong (3+/2+), granular immunostaining for
VEGF-A in 100% of tumor cells.
antibodies to evaluate MVD in various tumors [17, 22–26].
Our group had found in previous studies that the choice
of IHC marker used for endothelial cells detection may
influence the results, and the CD31 antibody as an endothelial
marker provides the most unequivocal and conspicuous
results [27]. CD31-highlighted endothelial cells are clearly
visible and easy to count. On the other hand, CD34 antibody
highlighted not only blood vessels but also other structures
in the vicinity, such as connective tissue fibers, and usually
CD34 gives much higher counts than CD31 [26]. Another
endothelial marker commonly used in assessing MVD is
endoglin (CD105). CD105 is a proliferation-associated and
hypoxia-inducible protein abundantly expressed in angio-
genic endothelial cells. Endoglin is a receptor for trans-
forming growth factor- (TGF-) beta1 and TGF-beta3, and
it modulates TGF-beta signalling. CD105 is required for
endothelial cell proliferation [28], and CD105-based MVD is
an independent prognostic factor for survival in patients with
some tumor types [29–31]. CD105 is strongly expressed in the
blood vessels of tumor tissues.
We have investigated the angiogenic status by comparing
vascular architecture,microvessel count (based on bothCD31
and CD105 IHC), and the expression of VEGFs in different
areas of benign and malignant PCC tumors.
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Figure 7: Positive (2+) immunostaining for VEGF-A in about 10%
of tumor cells.
Figure 8: Immunostaining for VEGF-C weakly positive (1+) in 20%
of tumor cells.
In the analyzed group of PPC, both benign and malig-
nant neoplasms were highly vascularized tumors. Vascular
architecture pattern was not equal, and vascular channels
had different shapes and sizes in different parts of the tumor.
Favier et al. had reported the differences in vascular archi-
tecture between benign and malignant PPC: benign tumors
exhibited a regular pattern of small vessels while malignant
PCC exhibited a more irregular pattern of vessels along with
the presence of larger vascular channels between tumor cell
nodules [24]. We have found highly heterogeneous vascular
architecture patterns within particular PCC tumors, both
benign and malignant. In areas with hemorrhagic and/or
cystic changes, relevant quantification of vascular patternwas
much more difficult and results were not always reliable.
Changing operating techniques (prevailing laparoscopic pro-
cedures) increases the incidence and extent of hemorrhages
in adrenal tumors (data prepared for publication) and there-
fore assessment of vascular architecture seems not to be a
reliable procedure in PCC.
Angiogenesis (NA) was evaluated by assessing MVD
using immunohistochemistry with CD31 and CD105 and
assessing the expression of VEGFs. We have found that the
MVD was higher in central areas of the tumor compared
with subcapsular areas for both vessel counting strategies and
with the use of both antibodies (CD31 and CD105). A strong
correlation was found between the numbers of CD31 and
Figure 9: Immunostaining for VEGF-D only focally positive (2+)
in single cells.
CD105 positive blood vessels in both subcapsular and central
areas of the tumors. The difference between the variables
for CD105 positive vessels was statistically significant (30.155
versus 37,91, Student’s 𝑡-test 𝑃 < 0.001). This could be
an indication that NA is more efficient in oxygen-reduced
central parts of the tumor. Low oxygen conditions activate
the hypoxia signaling pathway in neoplastic cells. Hypoxia-
inducible target genes mediate multiple biological functions
involved in the development of new blood vessels. Oxygen
deprivation shifts the balance between factors stimulating
and inhibiting angiogenesis toward the former.
We have also observed a strong correlation between the
number of macrophages (in both subcapsular and central
areas of the tumors) and MVD assessed by IHC with both
CD31 and CD105 and between expression of VEGF-A in the
tumor cells andMVD. Amore than twofold excess in VEGF-
A expression level was observed compared to VEGF-D levels.
Expression of VEGF-A was also higher than expression of
VEGF-C. The overexpression of VEGF-A and correlation
between the number of macrophages and MVD indicate
that neoangiogenesis in PCC is VEGF-A dependent and
macrophages are highly involved in the process. VEGF-C and
VEGF-D seem to be less involved in the vascularization of
PCC. As we have stated in a previous study, mast cells also
participate in vessel formation in PCC [32].
There are reports thatMVDcould influence the prognosis
of various solid tumors.The literature concerning angiogenic
status in PCC is still scanty and the results are ambiguous;
some authors had found an increase in vascular density
(MVD) in malignant versus benign PCC but some did
not confirm these results [23, 24, 33–39]. Our investigation
showed that there was no correlation between angiogenic
status of PCCs and their malignant (recurrent or metastatic)
behavior. We did not observe overexpression of any VEGFs
or higher MVD in malignant versus benign PCCs, but the
lack of significant differences in MVD and VEGF expression
between groups of PCC in our study may be due to a small
number of cases in the second investigated group. Increase
in MVD in malignant PCCs was previously described by
Favier in a group of PCCs, 50% of which harbour the
SDHB-mutation (so-called cluster 1 tumors, C1) and were
mostly extraadrenal PCCs (paragangliomas). The group of
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Table 6: Correlations between the expressions of VEGF-A and MVD (“hot spot” method).
CD31 CD105
Subcapsular Intratumoral Subcapsular Intratumoral
VEGF-C 𝑟 = 0.1757 𝑟 = 0.0637 𝑟 = 0.0999 𝑟 = −0.0227
VEGF-A 𝑟 = 0.3330 𝑟 = 0.4028 𝑟 = 0.4702 𝑟 = 0.4282
VEGF-D 𝑟 = −0.1068 𝑟 = −0.1526 𝑟 = −0.0193 𝑟 = −0.1338
Table 7: Vascular parameters in benign and malignant pheochromocytomas.
Marker Location Method Benign Malignant
Mean SD Mean SD
CD31
Subcapsular Hot spot 57.47 23.69 50.40 25.78
Intratumoral Hot spot 61.19 27.71 48.00 30.32
Subcapsular Chalkey 39.71 13.49 47.11 13.69
Intratumoral Chalkey 45.61 14.22 51.53 16.70
CD105
Subcapsular Hot spot 29.94 21.07 28.60 20.26
Intratumoral Hot spot 37.75 23.61 39.60 35.91
Subcapsular Chalkey 23.09 13.13 28.23 5.69
Intratumoral Chalkey 32.34 15.01 42.35 16.22
D2-40
Capsular Hot spot 1.87 1.32 2.50 1.73
Subcapsular Hot spot 0.11 0.57 0.20 0.45
Intratumoral Hot spot 0.00 0.00 0.00 0.00
VEGF-A 4.64 1.01 3.80 1.30
VEGF-C 3.60 1.12 3.40 0.89
VEGF-D 1.98 1.41 1.40 1.67
tumors analysed in our study consisted of 62 adrenal PPCs
in which SDH-mutations are very rare—only two of 62
tumors (3,2%) harbour SDHB-genemutations (data prepared
for publication). On the other hand, Ohij et al. reported
the absence of statistical association between MVD and
malignancy in PCC [38].
Lymphatic vessel density was analyzed in the same 62
PCC tumors after IHCwith the lymphatic endothelialmarker
D2-40. D2-40 labelling revealed a complete absence of lym-
phatic vessels in the central parts of all PCCs. We have found
single lymphatic vessels in 4 PCCs (6,4%) in subcapsular
areas and in 55 PCCs (88.7%) within the capsule. With only a
few lymphatic vessels that are found only in the subcapsular
areas of the tumor, it can be assumed that the spread through
lymphatics to lymphnodeswill bemuch rarer than the spread
by blood to distant organs.
For the majority of patients with both benign and malig-
nant PCC, the surgical removal of the tumor is the treatment
of choice. In malignant cases with distant metastases,
chemotherapy (CVD combination: cyclophosphamide,
vincristine, and dacarbazine), radiotherapy, and/or radio-
metabolic therapy using 131J-MIBG can also be used [39, 40].
These therapies may lead to remission and symptom relief
in up to 50% of patients [22, 40]. Even so, half of the
patients with malignant, metastatic PCC do not benefit from
these therapies, and there is a need to find other treatment
possibilities. Because all PCCs are highly vascularized neo-
plasms, malignant tumors may be candidates for molecular
targeted therapies, especially antiangiogenic therapies tar-
geting the vascular endothelial growth factor pathway. Mon-
oclonal anti-VEGF antibody (bevacizumab) and tyrosine
kinase inhibitors are already used in patients with advanced
renal carcinoma and gastrointestinal stromal tumors (GIST).
In summary, PCCs differed in vascular density in central
and subcapsular areas of the tumor, but there were no sta-
tistically significant differences in vascular density between
benign and malignant cases, so MVD is not appropriate to
differentiate between benign and malignant PPC. Moreover,
secondary changes in these tumors influence the results and
both vascular architecture and MVD are markedly disturbed
by hemorrhagic and cystic changes in PCCs. These changes
are partially caused by laparoscopic operation technique.
High MVD in all PCCs is a promising factor for antiangio-
genic therapy, especially in the subgroup of PCC belonging to
the cluster 1 group (with SDHX or VHL-gene mutation [22].
5. Conclusion
(1) Microvessel density, as a single feature, does not help
in differentiating malignant and benign PCC and has
no independent prognostic significance in PCC.
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(2) The results of assessing vascular architecture and
MVD are biased by secondary changes in tumor
tissue, especially hemorrhages and cystic changes.
(3) High MVD in all PCCs is a promising factor for
antiangiogenic therapy, especially in the subgroup of
malignant PCC belonging to the cluster 1 group (with
SDHX or VHL-gene mutation).
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